Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns?

Area of Science:

• Pediatric Psychiatry
• Pharmacovigilance
• Health Services Research

Background:

• The U.S. Food and Drug Administration (FDA) issued safety warnings regarding increased suicidality risk in children using antidepressants between June 2003 and October 2004.
• Research indicates a decrease in antidepressant prescriptions for children during this period, but the impact of specific FDA warnings on treatment patterns remains unclear.

Purpose of the Study:

• To investigate whether specific safety information from FDA warnings influenced treatment patterns for children with major depressive disorder.
• To examine changes in the use of specific antidepressants (paroxetine, fluoxetine) and patient monitoring following FDA safety communications.

Main Methods:

• Analysis of Thomson Reuters MarketScan claims data (2001-2005) for privately insured children with major depressive disorder (N=22,689).
• Construction of treatment episodes to assess adherence to FDA recommendations on antidepressant use and patient monitoring.
• Evaluation of treatment pattern changes in relation to evolving FDA risk information.

Main Results:

• The timing of FDA recommendations correlated with trends in prescribing paroxetine and fluoxetine for children initiating antidepressant treatment.
• No significant increase in outpatient visits, suggesting no improvement in patient monitoring, was observed among depressed children starting antidepressants.

Conclusions:

• FDA safety and benefit information influenced antidepressant prescribing practices but did not lead to increased outpatient follow-up for children.
• While FDA warnings prompted changes in some prescribing behaviors, not all disseminated recommendations were consistently implemented by healthcare providers.